John Overdeck’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$651K Sell
7,200
-2,400
-25% -$201K ﹤0.01% 3947
2026
Q1
$769K Buy
+9,600
New +$791K ﹤0.01% 3446
2021
Q4
Sell
-6,200
Closed -$702K 4440
2021
Q3
$702K Sell
6,200
-5,300
-46% -$605K ﹤0.01% 2950
2021
Q2
$1.19M Buy
+11,500
New +$1.08M ﹤0.01% 2326
2021
Q1
Sell
-7,900
Closed -$721K 3938
2020
Q4
$721K Buy
7,900
+1,800
+30% +$149K ﹤0.01% 2237
2020
Q3
$487K Buy
+6,100
New +$476K ﹤0.01% 2271
2020
Q1
Sell
-28,800
Closed -$2.24M 3313
2019
Q4
$2.24M Buy
28,800
+7,800
+37% +$609K 0.01% 1498
2019
Q3
$1.54M Buy
21,000
+12,000
+133% +$843K 0.01% 1630
2019
Q2
$554K Buy
+9,000
New +$544K ﹤0.01% 2417
2018
Q4
Sell
-5,400
Closed -$313K 3133
2018
Q3
$313K Sell
5,400
-53,700
-91% -$2.63M ﹤0.01% 2748
2018
Q2
$2.87M Buy
59,100
+48,000
+432% +$2.24M 0.01% 1380
2018
Q1
$516K Buy
+11,100
New +$482K ﹤0.01% 2453
2016
Q4
Sell
-6,000
Closed -$241K 3213
2016
Q3
$241K Sell
6,000
-9,000
-60% -$339K ﹤0.01% 2877
2016
Q2
$499K Buy
+15,000
New +$513K ﹤0.01% 2257

Other funds holding EW

John Overdeck's EW Position: Q2 2026 in Review

John Overdeck increased its Edwards Lifesciences (EW) stake by 45% in Q2 2026, buying an estimated $39.4M and bringing the position to 1,521,899 shares worth $138M. The position accounts for 0.1% of the portfolio, ranked #225.

John Overdeck first reported a position in EW in Q3 2013 and has held it in 42 quarters since. The position peaked at $229M in Q4 2022. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • John Overdeck held 1,521,899 shares of Edwards Lifesciences worth $138M as of Q2 2026.
  • John Overdeck bought 470,364 Edwards Lifesciences shares in Q2 2026, an estimated $39.4M.
  • Edwards Lifesciences made up 0.1% of John Overdeck's portfolio in Q2 2026, its #225 holding.
  • John Overdeck first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 42 quarters since.
  • John Overdeck's Edwards Lifesciences position peaked at $229M in Q4 2022.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.